Prescription drug · NDA
Proglycem (Diazoxide) NDC 0575-6200
Diazoxide 50 mg/mL · Suspension · Oral · Teva Pharmaceuticals USA, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0575-6200-30 | 00575620030 | 1 BOTTLE, DROPPER in 1 BOX (0575-6200-30) / 30 mL in 1 BOTTLE, DROPPERMarketed from Sep 30, 1990 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Proglycem
- Generic name (nonproprietary)
- diazoxide
- Active ingredients
- Diazoxide — 50 mg/mL
- Dosage form
- Suspension
- Route
- Oral
- Labeler
- Teva Pharmaceuticals USA, Inc.NDC labeler code 0575
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 017453
- Marketing start
- Listing expires
- Identifiers
- Product ID 0575-6200_451aa56d-e2e5-402f-843a-cddb5b3d37ddSPL ID 451aa56d-e2e5-402f-843a-cddb5b3d37ddSPL set ID b16c7832-2fd9-49af-b923-1dc0d91fd6e2RxCUI 197593, 207634UNII O5CB12L4FN
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400575620030followed by a unit qualifier and the quantityPackage 00575-6200-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsucce…
Excerpt only. Read the full label for complete information.
About NDC 0575-6200
- What is NDC 0575-6200?
- 0575-6200 is the product NDC for Proglycem (diazoxide), Diazoxide 50 mg/mL suspension, listed with the FDA by Teva Pharmaceuticals USA, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Proglycem (Diazoxide).
- What is the active ingredient?
- Diazoxide.
- Who is the labeler?
- Teva Pharmaceuticals USA, Inc., NDC labeler code 0575. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Proglycem?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.